Samsara BioCapital’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-399,637
| Closed | -$795K | – | 29 |
|
|
2025
Q2 | $795K | Hold |
399,637
| – | – | 0.16% | 24 |
|
|
2025
Q1 | $579K | Hold |
399,637
| – | – | 0.1% | 29 |
|
|
2024
Q4 | $827K | Sell |
399,637
-399,637
| -50% | -$750K | 0.11% | 34 |
|
|
2024
Q3 | $1.41M | Hold |
799,274
| – | – | 0.27% | 31 |
|
|
2024
Q2 | $11.6M | Hold |
799,274
| – | – | 2.42% | 11 |
|
|
2024
Q1 | $13.3M | Hold |
799,274
| – | – | 2.06% | 13 |
|
|
2023
Q4 | $12.8M | Hold |
799,274
| – | – | 2% | 14 |
|
|
2023
Q3 | $10.8M | Buy |
799,274
+200,000
| +33% | +$2.81M | 3.29% | 9 |
|
|
2023
Q2 | $10.3M | Sell |
599,274
-10,588
| -2% | -$164K | 1.81% | 11 |
|
|
2023
Q1 | $10.1M | Sell |
609,862
-200
| -0% | -$3.2K | 2.08% | 12 |
|
|
2022
Q4 | $10.2M | Hold |
610,062
| – | – | 2.2% | 12 |
|
|
2022
Q3 | $10.4M | Sell |
610,062
-152,515
| -20% | -$2.22M | 2.43% | 9 |
|
|
2022
Q2 | $8.34M | Buy |
+762,577
| New | +$9.06M | 2.22% | 13 |
|
Samsara BioCapital's HLVX Position: Q3 2025 in Review
Samsara BioCapital sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 399,637 shares — an estimated $795K sold.
Samsara BioCapital first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $13.3M in Q1 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Samsara BioCapital reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Samsara BioCapital sold 399,637 HilleVax shares in Q3 2025, an estimated $795K.
- Samsara BioCapital first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Samsara BioCapital's HilleVax position peaked at $13.3M in Q1 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Samsara BioCapital's 13F filing for Q3 2025, filed 14 Nov 2025.